Patent · US Expired

HRPCa9 and HRPCa10 nucleic acids and polypeptides

US6872811B1 · kind B1 · utility

18Cited by
1References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 30, 1998
Grant dateMar 29, 2005
Priority date
Expiry dateSep 30, 2018

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/136
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention concerns cDNA molecules encoding HRPCa 9 and HRPCa 10 both of which are constitutively expressed in the androgen-independent cell line, LN3 LNAcP and induced by testosterone in the androgen-dependent cell line, LNAcP.The invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention. The invention also provides screening assays which can be used to identify compounds useful for the treatment of prostate cancer (e.g., androgen-independent prostate cancer).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.